Breakpoints #128 – IDWeek 2025 Recap
Dec 19, 2025
A rapid roundup of late‑breaking trials and stewardship controversies from IDWeek 2025. They survey new oral and IV antimicrobials, safety signals like ceftriaxone events, and evolving PK/PD data for oral step‑downs. The conversation spans antifungal and HIV cure advances, debates on vancomycin and bacteremia duration, and practical implications for outpatient use and formularies.
AI Snips
Chapters
Transcript
Episode notes
BNAbs May Help Achieve HIV Post‑Treatment Control
- Broadly neutralizing antibodies plus early ART show promise delaying viral rebound and reducing reservoir size in small trials.
- These strategies hint at potential post-treatment control but remain investigational.
Shorter Bacteremia Courses Hold For Most Patients
- The BALANCE trial supports 7‑day vs 14‑day courses for many bloodstream infections, but subgroup analyses didn't isolate who needs longer therapy.
- Very low‑risk patients might do even better with shorter courses—research is ongoing.
Treat Male Partners To Reduce BV Recurrence
- For male partners of women with recurrent BV, offer partner treatment with oral metronidazole plus topical clindamycin to reduce recurrence.
- Emphasize adherence, especially to topical regimens, to maximize benefit.